Non-small cell lung cancer · line 2 · Lorlatinib monotherapy (ALK+ NSCLC, 1L OR post-2G TKI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-LORLATINIB-NSCLC |
| ID | IND-NSCLC-ALK-2L-LORLATINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for ALK+ NSCLC post-2nd-gen TKI failure. Reuses existing REG-LORLATINIB-NSCLC. CROWN expanded role to 1L; sequencing decision driven by access + center experience. Repotrectinib (TRIDENT-1) is the next-generation ALK/ROS1 TKI for post-lorlatinib failure — separate future Indication.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L